PURPOSE: To assess the reproducibility of intrinsic relaxivity and both relaxivity- and susceptibility-based dynamic contrast enhanced (DCE) MRI in pelvic tumors; to correlate kinetic parameters obtained and to assess whether acute antivascular effects are seen in response to cisplatin- or taxane-based chemotherapy. MATERIALS AND METHODS: T1-weighted and T2*-weighted DCE-MRI and basal R2* measurements were performed on three consecutive days in women with gynecological tumors. The third scan was 21.0 (range 17.3-23.5) hours after the first cycle of chemotherapy. Kinetic parameter estimates were obtained and correlated between techniques. Test-retest reproducibility and response to treatment were assessed. RESULTS: Relative blood volume (rBV) and relative blood flow (rBF) correlated strongly with transfer constant (Ktrans), kep, and the initial area under the gadopentetate dimeglumine (Gd-DTPA) concentration-time curve (IAUGC) (all P<0.01). The group 95% confidence interval (CI) for change was -10.8 to +12.1%; +/-5.1%; -9.5 to +10.5%; +/-7.5%; for Ktrans, ve, kep, and IAUGC, respectively, and +/-13.6%, +/-2.4%, +/-11.6%, and +/-11.0%, for rBV, mean transit time (MTT), rBF, and R2*, respectively. There were no significant acute changes in kinetic parameter estimates in response to treatment on group analysis, apart from a small decrease in ve. CONCLUSION: The results confirm the dominant influence of flow on Ktrans in untreated gynecological tumors. There is no evidence of an acute, large magnitude antivascular effect caused by cisplatin- or taxane-based chemotherapy. Copyright (c) 2007 Wiley-Liss, Inc.
PURPOSE: To assess the reproducibility of intrinsic relaxivity and both relaxivity- and susceptibility-based dynamic contrast enhanced (DCE) MRI in pelvic tumors; to correlate kinetic parameters obtained and to assess whether acute antivascular effects are seen in response to cisplatin- or taxane-based chemotherapy. MATERIALS AND METHODS: T1-weighted and T2*-weighted DCE-MRI and basal R2* measurements were performed on three consecutive days in women with gynecological tumors. The third scan was 21.0 (range 17.3-23.5) hours after the first cycle of chemotherapy. Kinetic parameter estimates were obtained and correlated between techniques. Test-retest reproducibility and response to treatment were assessed. RESULTS: Relative blood volume (rBV) and relative blood flow (rBF) correlated strongly with transfer constant (Ktrans), kep, and the initial area under the gadopentetate dimeglumine (Gd-DTPA) concentration-time curve (IAUGC) (all P<0.01). The group 95% confidence interval (CI) for change was -10.8 to +12.1%; +/-5.1%; -9.5 to +10.5%; +/-7.5%; for Ktrans, ve, kep, and IAUGC, respectively, and +/-13.6%, +/-2.4%, +/-11.6%, and +/-11.0%, for rBV, mean transit time (MTT), rBF, and R2*, respectively. There were no significant acute changes in kinetic parameter estimates in response to treatment on group analysis, apart from a small decrease in ve. CONCLUSION: The results confirm the dominant influence of flow on Ktrans in untreated gynecological tumors. There is no evidence of an acute, large magnitude antivascular effect caused by cisplatin- or taxane-based chemotherapy. Copyright (c) 2007 Wiley-Liss, Inc.
Authors: Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw Journal: Cancer Date: 2011-12-16 Impact factor: 6.860
Authors: M J Gollub; D H Gultekin; O Akin; R K Do; J L Fuqua; M Gonen; D Kuk; M Weiser; L Saltz; D Schrag; K Goodman; P Paty; J Guillem; G M Nash; L Temple; J Shia; L H Schwartz Journal: Eur Radiol Date: 2011-11-20 Impact factor: 5.315
Authors: Esme J Hill; Corran Roberts; Jamie M Franklin; Monica Enescu; Nicholas West; Thomas P MacGregor; Kwun-Ye Chu; Lucy Boyle; Claire Blesing; Lai-Mun Wang; Somnath Mukherjee; Ewan M Anderson; Gina Brown; Susan Dutton; Sharon B Love; Julia A Schnabel; Phil Quirke; Ruth Muschel; William G McKenna; Michael Partridge; Ricky A Sharma Journal: Clin Cancer Res Date: 2016-02-09 Impact factor: 12.531
Authors: I M E Desar; E G W ter Voert; Th Hambrock; J J A van Asten; D J van Spronsen; P F A Mulders; A Heerschap; W T A van der Graaf; H W M van Laarhoven; C M L van Herpen Journal: Cancer Imaging Date: 2012-01-12 Impact factor: 3.909
Authors: Chaan S Ng; Wei Wei; James A Bankson; Murali K Ravoori; Lin Han; David W Brammer; Sherry Klumpp; John C Waterton; Edward F Jackson Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240